Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04403516
Other study ID # Dextenza in Pterygium Surgery
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 1, 2020
Est. completion date August 5, 2021

Study information

Verified date April 2022
Source New York Eye Specialists
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

DEXTENZA for the treatment of post-surgical pain and inflammation compared to standard of care topical prednisolone acetate 1% in patients who undergo pterygium surgery (excision of pterygium with conjunctival autograft)


Description:

In patients who undergo pterygium surgery, eyes will be consecutively assigned to receive either DEXTENZA or topical prednisolone acetate 1%.15 eyes will receive a Dextenza insertion into both the upper and lower puncta at the time of surgery, followed by at postoperative month 1 visit institution of topical prednisolone acetate 1% bid x 2 weeks then qd x 2 weeks then discontinued. 15 eyes will receive starting on postoperative day 1 topical prednisolone acetate 1% q2 hours x 2 weeks then qid for 2 weeks then bid for 2 weeks then qd for 2 weeks then discontinued.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date August 5, 2021
Est. primary completion date August 5, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: A patient's study eye must meet the following criteria to be eligible for inclusion in the study: • Age of at least 18 years with primary pterygia Exclusion Criteria: A patient who meets any of the following criteria will be excluded from the study: - Glaucoma - Ocular hypertension - Prior conjunctival surgery - Other uncontrolled ocular disease - Ocular surgery in either eye within 3 months - Use of eye drops other than postoperative medications and artificial tears

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dexamethasone Intracanalicular Insert, 0.4mg
To determine post-surgical resolution of pain and inflammation outcomes with DEXTENZA compared to topical steroid treatment in patients who undergo pterygium surgery.
Prednisolone Acetate 1%
To reduce post-surgical pain and inflammation in patients who undergo pterygium surgery.

Locations

Country Name City State
United States New York Eye Specialists New York New York

Sponsors (2)

Lead Sponsor Collaborator
Michelle Rhee MD Ocular Therapeutix, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient satisfaction-comfort and convenience Assessed by patient reported questionnaire Assessed on Post-Op Day 1
Primary Patient satisfaction-comfort and convenience Assessed by patient reported questionnaire Assessed on Week 1
Primary Patient satisfaction-comfort and convenience Assessed by patient reported questionnaire Assessed on Month 1
Primary Patient satisfaction-comfort and convenience Assessed by patient reported questionnaire Assessed on Month 3
Primary Patient satisfaction-comfort and convenience Assessed by patient reported questionnaire Assessed on Month 6
Secondary To compare the degree of conjunctival hyperemia Assessed by clinical external photography Assessed on Week 1
Secondary To compare the degree of conjunctival hyperemia Assessed by clinical external photography Assessed on Month 1
Secondary To compare the degree of conjunctival hyperemia Assessed by clinical external photography Assessed on Month 2
Secondary To compare the degree of conjunctival hyperemia Assessed by clinical external photography Assessed on Month 3
Secondary To compare the degree of conjunctival hyperemia Assessed by clinical external photography Assessed on Month 6
Secondary Mean number of days for corneal re-epithelialization As evaluated by slit lamp examination Assessed on Post-Op Day 1
Secondary Mean number of days for corneal re-epithelialization As evaluated by slit lamp examination Assessed on Week 1
Secondary Mean number of days for corneal re-epithelialization As evaluated by slit lamp examination Assessed on Month 1
Secondary Recurrence of pterygium As measured by yes or no on recurrence; external eye examination Assessed at Month 1
Secondary Recurrence of pterygium As measured by yes or no on recurrence; external eye examination Assessed at Month 2
Secondary Recurrence of pterygium As measured by yes or no on recurrence; external eye examination Assessed at Month 3
Secondary Recurrence of pterygium As measured by yes or no on recurrence; external eye examination Assessed at Month 6
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02641132 - Pterygium Head Body MMC1: Two Different Surgical Procedures and Their Effect on Endothelial Cell Count. Phase 4
Completed NCT02342392 - Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study Phase 2/Phase 3
Recruiting NCT01387971 - Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders N/A
Recruiting NCT05978687 - The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision Phase 4
Not yet recruiting NCT06042296 - Expression of CD44, PCNA and E-cadherin in Pterygium Tissue
Completed NCT04022811 - Effect of Bromfenac on Pain Related to Pterygium Surgery Phase 4
Recruiting NCT01261455 - Prospective Randomized Pilot Study Comparing Inferior Versus Superior Conjunctival Autografts for Primary Pterygia N/A
Recruiting NCT01249235 - Bandage Contact Lens and Oral Analgesics Versus Patching and Oral Analgesics for Pain Following Pterygium Surgery N/A
Completed NCT01115517 - Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery Phase 2
Completed NCT00768963 - Ranibizumab for the Inhibition of Neovascularization in Pterygia Phase 1
Completed NCT00949728 - Conjunctival Autologous Transplantation Using Fibrin Glue in Primary Pterygia N/A
Recruiting NCT00563277 - Surgical Treatment of Concurrent Cataract and Primary Pterygium N/A
Completed NCT00346450 - Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Phase 3
Completed NCT03533244 - A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia Phase 2
Recruiting NCT02911532 - Tissue Engineering Conjunctiva for the Treatment of Pterygium and Atretoblepharia N/A
Not yet recruiting NCT03304366 - Corneal Changes With Pentacam Before and After Pterygium N/A
Unknown status NCT02015000 - Surgical Result of Pterygium Extended Removal Followed by Fibrin Glue Assisted Amniotic Membrane Transplantation N/A
Completed NCT00344201 - Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of External Eye Surgery Phase 1
Recruiting NCT00326560 - Comparison of Glue With Sutures for Pterygium Surgery Phase 3
Not yet recruiting NCT03314389 - The Corneal and Conjunctiva Sensation Before and After Pterygium Surgeries N/A